Autor: | Betty Tyler, Jon D. Weingart, Phillip B. Storm, John L. Moriarity, Peter C. Burger, Henry Brem |
---|---|
Rok vydání: | 2002 |
Předmět: |
Cancer Research
Biodistribution Chemotherapy Gliosarcoma business.industry medicine.medical_treatment Pharmacology medicine.disease Biodegradable polymer Neurology Oncology Pharmacokinetics In vivo Glioma Immunology polycyclic compounds medicine heterocyclic compounds Neurology (clinical) biological phenomena cell phenomena and immunity business neoplasms Camptothecin medicine.drug |
Zdroj: | Journal of Neuro-Oncology. 56:209-217 |
ISSN: | 0167-594X |
Popis: | Camptothecin is a potent antineoplastic agent that has shown efficacy against multiple tumor lines in vitro; unfortunately, systemic toxicity has limited its in vivo efficacy. This is the first study to investigate the release, biodistribution, and efficacy of camptothecin from a biodegradable polyanhydride polymer. Tritiated camptothecin was incorporated into biodegradable polymers that were implanted intracranially in 16 male Fischer 344 rats and the animals were followed up to 21 days post-implant. A concentration of 11–45 μg of camptothecin-sodium/mg brain tissue was within a 3 mm radius of the polymer disc, with levels of 0.1 μg at the outermost margin of the rat brain, 7 mm from the site of implantation. These tissue concentrations are within the therapeutic ranges for human and rat glioma lines tested against camptothecin-sodium in vitro. The in vivo efficacy of camptothecin-sodium was evaluated with male Fischer 344 rats implanted intracranially with 9L gliosarcoma and compared with the efficacy of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). The animals were divided into four groups. Group 1 (control) had a median survival of 17 days. Group 2 (3.8% BCNU polymer) had a median survival of 23 days (P=0.006). Group 3 (20% camptothecin polymer) had a median survival of 25 days (P=0.023). Group 4 (50% camptothecin polymer) had a median survival of 69 days (P |
Databáze: | OpenAIRE |
Externí odkaz: |